Altimmune (Nasdaq: ALT) announced its upcoming presentation at the EASL International Liver Congress™ 2025 in Amsterdam. The company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) using the MASH Resolution Index (MASHResInd), a new non-invasive measure of MASH histologic response. Dr. Shaheen Tomah, Director of Clinical Development at Altimmune, will present findings on MASH resolution rates with pemvidutide treatment. The presentation includes a poster tour on May 8, 2025, at 9:45 am CET and a general poster session on May 10, 2025, from 12:00 PM to 1:00 PM CET.
Altimmune (Nasdaq: ALT) ha annunciato la sua prossima presentazione al EASL International Liver Congress™ 2025 ad Amsterdam. L'azienda presenterà analisi su soggetti trattati con pemvidutide affetti da steatosi epatica associata a disfunzione metabolica (MASLD) utilizzando il MASH Resolution Index (MASHResInd), un nuovo metodo non invasivo per valutare la risposta istologica alla MASH. Il dott. Shaheen Tomah, Direttore dello Sviluppo Clinico di Altimmune, illustrerà i risultati sui tassi di risoluzione della MASH con il trattamento pemvidutide. La presentazione comprende un tour del poster l'8 maggio 2025 alle 9:45 CET e una sessione generale di poster il 10 maggio 2025 dalle 12:00 alle 13:00 CET.
Altimmune (Nasdaq: ALT) anunció su próxima presentación en el EASL International Liver Congress™ 2025 en Ámsterdam. La compañía presentará análisis de sujetos tratados con pemvidutide que padecen enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD), utilizando el MASH Resolution Index (MASHResInd), una nueva medida no invasiva de la respuesta histológica a MASH. El Dr. Shaheen Tomah, Director de Desarrollo Clínico en Altimmune, presentará los hallazgos sobre las tasas de resolución de MASH con el tratamiento de pemvidutide. La presentación incluye un recorrido por el póster el 8 de mayo de 2025 a las 9:45 am CET y una sesión general de pósters el 10 de mayo de 2025 de 12:00 pm a 1:00 pm CET.
Altimmune(Nasdaq: ALT)는 암스테르담에서 열리는 EASL International Liver Congress™ 2025에서의 발표를 예고했습니다. 회사는 대사 기능 장애 연관 지방간 질환(MASLD) 환자에게 pemvidutide 치료를 적용한 분석 결과를, MASH 조직학적 반응의 새로운 비침습적 지표인 MASH Resolution Index(MASHResInd)를 사용해 발표할 예정입니다. Altimmune 임상개발 책임자인 Shaheen Tomah 박사가 pemvidutide 치료에 따른 MASH 해소율에 관한 연구 결과를 발표합니다. 발표는 2025년 5월 8일 오전 9시 45분 CET에 포스터 투어, 2025년 5월 10일 정오부터 오후 1시까지 CET에 일반 포스터 세션으로 진행됩니다.
Altimmune (Nasdaq : ALT) a annoncé sa prochaine présentation lors du EASL International Liver Congress™ 2025 à Amsterdam. La société présentera des analyses de sujets traités par pemvidutide atteints de maladie hépatique stéatosique associée à une dysfonction métabolique (MASLD) en utilisant le MASH Resolution Index (MASHResInd), une nouvelle mesure non invasive de la réponse histologique à la MASH. Le Dr Shaheen Tomah, directeur du développement clinique chez Altimmune, présentera les résultats sur les taux de résolution de la MASH avec le traitement pemvidutide. La présentation comprend une visite du poster le 8 mai 2025 à 9h45 CET et une session générale de posters le 10 mai 2025 de 12h00 à 13h00 CET.
Altimmune (Nasdaq: ALT) gab seine bevorstehende Präsentation auf dem EASL International Liver Congress™ 2025 in Amsterdam bekannt. Das Unternehmen wird Analysen von mit Pemvidutide behandelten Patienten mit metabolisch bedingter steatotischer Lebererkrankung (MASLD) unter Verwendung des MASH Resolution Index (MASHResInd), einem neuen nicht-invasiven Maß zur histologischen Reaktion bei MASH, vorstellen. Dr. Shaheen Tomah, Direktor der klinischen Entwicklung bei Altimmune, wird Ergebnisse zur MASH-Auflösungsrate unter Pemvidutide-Therapie präsentieren. Die Präsentation umfasst eine Poster-Tour am 8. Mai 2025 um 9:45 Uhr MEZ sowie eine allgemeine Postersession am 10. Mai 2025 von 12:00 bis 13:00 Uhr MEZ.
Positive
None.
Negative
None.
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive non-invasive measure of MASH histologic response, in a poster session at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2025 in Amsterdam, The Netherlands. The abstract will be featured in the conference poster session and poster tour.
Details of the presentations are as follows:
Title: MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)
Date/Time: Saturday, May 10, 2025, from 12:00 PM to 1:00 PM CET
A copy of the poster will be accessible on the Events section of the Altimmune website.
About Pemvidutide Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of obesity, MASH, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial. IND applications in AUD and ALD have received FDA clearance with Phase 2 trials to commence in mid-2025.
About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter
Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com
Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com
This press release was published by a CLEAR® Verified individual.
FAQ
What will Altimmune (ALT) present at EASL International Liver Congress 2025?
Altimmune will present analyses of pemvidutide-treated subjects with MASLD using the MASH Resolution Index, focusing on MASH resolution rates with pemvidutide treatment.
When and where is Altimmune's presentation at EASL 2025?
The presentations will be held in Amsterdam, with a poster tour on May 8, 2025 at 9:45 am CET and a general poster session on May 10, 2025 from 12:00 PM to 1:00 PM CET.
Who will present Altimmune's MASH resolution data at EASL 2025?
Dr. Shaheen Tomah, Director of Clinical Development at Altimmune, will present the data.
What is the MASH Resolution Index that Altimmune will discuss?
The MASH Resolution Index (MASHResInd) is a highly sensitive non-invasive measure of MASH histologic response, developed by Loomba in 2024.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
